Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...

Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the ...

Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

Oral vancomycin therapy resulted in clinical response in nearly half of patients with inflammatory bowel disease associated ...

Ctexli’s approval further entrenches Mirum as a leader in rare liver diseases, alongside its cornerstone product Livmarli and ...

(GILD) announced that the European Commission has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis in combination with ursodeoxycholic ...

Gilead Sciences’ seladelpar has been granted conditional marketing authorisation by the European Commission (EC) to treat ...

Primary sclerosing cholangitis (PSC) is a progressive scarring of the liver's bile ducts. According to current estimates, between 5 and 16 in every 100,000 people have PSC. The symptoms of PSC ...

Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...